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Mixed lipid aggregates, comprising of bile salts and phospholipids, present in the small 15 
intestine assist in drug solubilization and subsequent drug dissolution and absorption through 16 
the intestinal epithelium. The increased variability in their levels, observed physiologically, 17 
may create challenges not only for in vivo bioavailability and bioequivalence studies, but also 18 
for in vitro bio-predictive studies as correlations between in vitro and in vivo data are not always 19 
successful. The current study investigated the impact of biorelevant dissolution media, with 20 
physiologically relevant sodium taurocholate and lecithin levels, on the apparent solubility and 21 
affinity of lipophilic compounds with a wide range of physicochemical properties (drug 22 
ionization, drug lipophilicity, molecular weight) to mixed lipid aggregates. Apparent solubility 23 
data in biorelevant dissolution media for the studied neutral drugs, weak bases and weak acids 24 
were compared against a phosphate buffer pH 6.5 in the absence of these lipidic components. 25 
Presence of mixed lipid aggregates enhanced the apparent solubility of the majority of 26 
compounds and the use of multivariate data analysis identified the significant parameters 27 
affecting drug affinity to mixed lipid aggregates based on the chemical class of the drug. For 28 
neutral drugs, increasing bile salt concentrations and/or drug lipophilicity resulted in greater 29 
enhancement in apparent solubility at 24-hr. For weak bases and weak acids, the effect of 30 
increasing bile salt levels on apparent solubility depended mostly on an interplay between drug 31 
lipophilicity and drug ionization.  32 
Keywords: drug lipophilicity, ionization, solubilization, affinity, mixed lipid aggregates, 33 





1. Introduction 37 
The lipophilic nature of drug target proteins results in the identification of lipophilic 38 
compounds as successful drug candidates by high-throughput screening 1. Although 39 
pharmacologically active, lipophilic drugs suffer from poor aqueous solubility which presents 40 
several absorption challenges for oral administration. Only dissolved drug molecules are 41 
capable of permeating through the gastrointestinal epithelium Low aqueous solubility can 42 
therefore impede oral drug absorption and subsequently oral drug bioavailability. Varying 43 
approaches are employed during product development to increase drug solubility and improve 44 
product performance (e.g. salt formation, crystal structure modification, use of surfactants, 45 
enabling formulations) 2. In vivo, a number of gastrointestinal factors may influence drug 46 
solubility and improve (or impede) oral drug absorption. The pH of gastrointestinal fluids is 47 
critical for the solubility of ionizable compounds, as ionized molecules exhibit higher solubility 48 
than their neutral form. Presence of natural solubilizing components (e.g. bile salts, 49 
phospholipids, and ingested lipids) in gastrointestinal fluids play a key role in solubilizing 50 
lipophilic compounds and enhance their dissolution, solubility and finally absorption and 51 
bioavailability. 52 
Bile salts are amphiphilic molecules present in the gastrointestinal tract with a key role in 53 
the digestion of dietary fat and absorption of lipophilic compounds 3. Primary bile acids are 54 
produced by the hepatocytes, stored and converted to salts in the gall bladder, until they are 55 
secreted to the duodenum once acid chyme enters the small intestine 3. A number of bile acids 56 
are produced in vivo, with cholic and chenodeoxycholic acid (further conjugated with glycine 57 
and taurine forming the corresponding bile salts) being the most predominant  forms 4. Bile 58 
salts are steroidal molecules and differ in the number, position and stereochemistry of the 59 
hydroxy groups in the steroid structure3. At low concentrations and due to their amphiphilic 60 
nature, bile salts act as surfactants facilitating the wetting of the administered formulation 5. At 61 
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increased concentrations [above the critical micellar concentration (CMC)], bile salts self-62 
assemble into aggregates  (spherical, rod or lamellar shaped) 3 and can solubilize lipophilic 63 
compounds. A suggested mechanism by which bile salt aggregates are formed includes a 64 
stepwise process in which the hydrophobic parts come in contact exposing the hydrophilic head 65 
to the solvent (formation of primary micelles) 6. Primary micelles can further aggregate into 66 
secondary aggregates via intermicellar H-bonding among the hydrophilic parts 6. In the 67 
presence of natural phospholipids (e.g. phosphatidylcholine, lysolecithin, 68 
phosphatidylglycerol, diphosphatidylglycerol, sphingomyelin) 7, which are secreted with the 69 
bile into the duodenum, mixed lipid (bile salt:phospholipid) aggregates are formed which 70 
exhibit greater stability and solubilizing capacity compared to aggregates comprising only bile 71 
salts. 72 
The composition, levels and structure of mixed aggregates in vivo show high variability, 73 
due to inter/intra subject variations or certain disease states. This variability affects the 74 
solubilizing capacity of these aggregates may influence oral drug bioavailability. Structurally 75 
differing bile salts are excreted into the small intestine. Studies evaluating the composition of 76 
human intestinal fluids report taurocholic, taurochenodeoxycholic, taurodeoxycholic, 77 
glycocholic, glycochenodeoxycholic and glycodeoxycholic salts as the main bile components 78 
present in the duodenum 8. It has been suggested that the varying degree of hydroxylation of 79 
these bile components may influence the solubilizing capacity of the formed mixed lipid 80 
aggregates 7,9. Regional differences in the bile salt levels are known. Bile salts are primarily 81 
present in the small intestine, while small amounts (1 mM) in stomach (in the fasted or fed 82 
state) due to duodenal reflux have been reported in literature 10. In the fasted duodenum, the 83 
bile salt concentrations vary but are significantly higher than the ones in the stomach. Large 84 
variations in their level are found in human aspirates ranging between 0.03-36.18 mM 8 with 85 
mean and median values in the average range of 1.4-8.1 mM 8. Post meal administration, the 86 
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bile salt concentrations rise even further and range between 0.74-86.14 mM 8 with mean and 87 
median values in the range of 3.6-24 mM 8. As the solubilizing capacity of mixed lipid 88 
aggregates (and also drug solubility) increases as a function of taurocholate and lecithin 89 
concentration, variations in their levels are rendered critical in vivo and need to be accounted 90 
for in in vitro experimental setups. For patients with gastrointestinal diseases, changes in the 91 
bile salts concentrations are also known 11. The supramolecular structure of the lipidic phase 92 
itself may vary in vivo. Characterization of human aspirates revealed the presence of micelles 93 
of diverse composition and distinct size fractions [pure cholate or cholate-rich micelles (< 20 94 
nm) and mixed cholate/phospholipid micelles or phospholipid vesicles (50-200 nm)] 12,13. The 95 
solubilizing capacity of these different phases varies and may significantly oral drug absorption 96 
14. 97 
As the use of human aspirates for in vitro experimentation to assess product performance 98 
is not always feasible or practical, due to availability, cost and variability, biorelevant media 99 
have been developed to reflect the composition of different gastrointestinal fluids. These media 100 
are constantly reviewed and updated to better reflect in vivo conditions in terms of pH, buffer 101 
capacity, osmolarity, composition and concentration of amphiphilic components (sodium 102 
taurocholate, lecithin) 15,16. Although each update improves the biorelevance of these media, 103 
deviations in drug solubility values between simulated fluids and human aspirates still prevail 104 
17. The observed increased variability in the concentrations of certain gastrointestinal 105 
components in vivo has been a matter of concern lately 18-20 and may explain the in vitro-in 106 
vivo discrepancies in drug solubility. 107 
The aim of this study was to investigate the affinity of lipophilic compounds to mixed lipid 108 
aggregates present in gastrointestinal fluids. The impact of mixed lipid aggregates on drug 109 
apparent solubility was studied in a biopharmaceutical perspective. Biorelevant dissolution 110 
media, with varying levels of amphiphilic components, were used to assess drug’s affinity to 111 
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the micellar phases simulating the fasted state gastrointestinal conditions. Drug-specific 112 
interactions with mixed lipid aggregates were investigated by selecting lipophilic compounds 113 
with varying physicochemical (drug ionization, logDpH6.5, molecular properties) and molecular 114 
properties. Multivariate data analysis [Partial Least squares (PLS)] was used to identify the 115 
critical drug properties affecting compound solubilization and partitioning to the lipidic mixed 116 
aggregates. 117 
2. Materials and Methods 118 
2.1 Materials 119 
APIs: Carvedilol, corticosterone, dipyridamole, indoprofen, naproxen, and warfarin were 120 
obtained from Sigma-Aldrich, UK. Astemizole, cinnarizine, griseofulvin, haloperidol, 121 
indomethacin, tamoxifen and tolfenamic acid were purchased from Alfa Aesar, UK. 122 
Disopyramide was purchased from MP biomedicals, UK. Progesterone was purchased from 123 
Merck Millipore, UK Chemicals: High Performance Liquid Chromatography (HPLC) 124 
methanol and acetonitrile were purchased from VWR, UK. Sodium chloride and sodium 125 
hydroxide were acquired from Fisher Scientific, UK. The Fasted State Simulated Intestinal 126 
Fluid (FaSSIF)/Fed State Simulated Intestinal Fluid (FeSSIF)/Fasted State Simulated Gastric 127 
Fluid (FaSSGF) powder was purchased from Biorelevant, UK. Water was ultra-pure (Milli-Q) 128 
laboratory Grade. Consumables: Syringe filters Polytetrafluoroethylene (PTFE) 0.45 µm pore 129 
size (Fisherbrand, UK) and Cronus Regenerated Cellulose (RC) 0.45 µm pore size (LabHut, 130 
UK) were obtained from the specified sources. Instrumentation: Fisherbrand waterbath 131 
(Fisher Scientific, UK), Mettler Toledo SevenCompact S210 pH meter (Schwerzenbach, 132 
Switzerland), Agilent Technologies 1200 series HPLC system (Santa Clara, CA): binary pump 133 
(G1311A), autosampler (G1329A), thermostatted column compartment (G1316A), and diode 134 
array detector (G1315A). 135 
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2.2. Methods 136 
2.2.1 Compound selection for solubility studies 137 
The selected compounds for the apparent solubility studies are presented in Table 1. 138 
Compounds were selected to cover a wide range of physicochemical properties associated with 139 
drug affinity to mixed lipid aggregates 21. Drug were categorized based on their drug ionization 140 
on pH 6.5 (low ionization: Fion <50%, high ionization: Fion ≥ 50%), drug lipophilicity [low 141 
lipophilicity: log DpH 6.5 (logarithm of the octanol:water partition coefficient at pH 6.5) < 0, 142 
medium lipophilicity: 0 ≤ log DpH 6.5 < 2, high lipophilicity: log DpH 6.5 ≥ 2] and molecular 143 
weight (medium molecular weight: 200 ≤ MW  < 500, high molecular weight: MW ≥ 500). 144 
The structure of the studied compounds is presented in Figure 1. The molecular descriptors 145 
(polar surface area, rotatable bonds, hydrogen bond donors and hydrogen bond acceptors) of 146 
the studied compounds are presented in Supplementary Table 1. 147 
2.2.2. Preparation of solubility media 148 
The composition of the solubility media is presented in Table 2. The phosphate buffer 149 
(PhBpH 6.5), not containing bile salts, was prepared at room temperature by dissolving 0.420 g 150 
of NaOH, 3.438 g of NaH2PO4 and 6.186 g of NaCl in 0.9 L of deionized water. The pH was 151 
adjusted to 6.5 and the volume was filled up to 1 L with deionized water. The biorelevant 152 
dissolution media (BDM), containing different bile salt and phospholipid concentrations, were 153 
prepared by dissolving SIF powder to the PhBpH 6.5. All SIF media were freshly prepared and 154 
allowed to stand for 2 hr, to achieve equilibration 22, in room temperature until a slightly 155 
opalescent micellar solution was obtained. The studied bile salt levels were selected to reflect 156 
the physiological variability e.g. i. Biorelevant dissolution media with low taurocholate and 157 
lecithin concentrations (BDML): achlorhydric conditions in the fasted stomach and ii. 158 
Biorelevant dissolution media with medium (BDMM) and high (BDMH) mixed lipid aggregate 159 
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concentrations: media covering closely the low and upper limits in the mean and median bile 160 
salt levels reported at fasted state in vivo, as explained in Section 1. Studies suggest that the 161 
CMC of taurocholate lies between 1-12 mM or that taurocholate exhibits no strict CMC and 162 
forms smaller aggregates at increasing levels 22,23. Under the studied concentrations therefore, 163 
mixed lipid aggregates, rather than micelles, are expected to be formed in the BDMs. 164 
2.2.3. Solubility studies 165 
Drug solubility studies in the PhBpH 6.5 and BDMs were performed in triplicate using the 166 
shake-flask method 24. An excess amount of drug (approximately three times higher than the 167 
estimated equilibrium drug solubility) was weighed in labelled eppendorf tubes. 5 mL of each 168 
solubility medium was added in the tubes. The samples were vortexed and placed in a shaking 169 
water bath [37 °C, 200 strokes per minute (spm)]. To be noted, that stability issues of the mixed 170 
lipid aggregates are not expected when heating the BDMs at 37°C for 24 hr 22. At 24 hr, 500 171 
μL were sampled and filtered through PTFE filters. Filter adsorption studies were prior 172 
performed in triplicate for each drug. No adsorption issues onto the filters used were observed 173 
for the studied drugs. Filtered samples were further diluted (if needed) with the corresponding 174 
mobile phase and analysed by HPLC-UV. Analytical HPLC procedures were based on 175 
modification of methods taken from the literature (Supplementary Table 2). Drug 176 
quantification was made based on calibration curves. Standards were prepared from 177 
concentrated stock solutions consisting of drug dissolved in an organic solvent. 178 
2.2.4 Data Treatment 179 
Solubility data at 24-hr in PhBpH6.5 were expressed in molarity. Differences in the apparent 180 
drug solubility between the PhBpH 6.5 and the BDMs were expressed as the logarithm of the 181 
Solubility Ratio (logSR), calculated based on Equation 1 182 
𝑙𝑜𝑔𝑆𝑅 = 𝑙𝑜𝑔 ( 
𝑆𝐵𝐷𝑀
𝑆𝑃ℎ𝐵6.5
 )  Equation 1 183 
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where 𝑆𝐵𝐷𝑀 and 𝑆𝑃ℎ𝐵6.5 denote drug apparent solubility in the BDM and PhBpH 6.5, respectively 184 
at 24 hr. logSR< 0, logSR= 0 and logSR> 0 indicate reduced, equal and higher, respectively, 185 
apparent drug solubility in the BDM when compared to PhBpH6.5. 186 
Graphs depicting the logSR of the mixed aggregates on drug apparent solubility at 24-hr 187 
were constructed using GraphPad Prism (GraphPadPrism, USA). Linear regressions of drug 188 
apparent solubility (μM) as a function of bile salt concentrations (mM) were performed using 189 
GraphPad Prism (GraphPad Prism, USA), and the slopes and R2 of each regression line were 190 
calculated automatically by the software.  191 
Hansen solubility parameters, describing solutes and solvents in terms of intermolecular 192 
dispersion forces (D), polarity forces (P) and hydrogen bond forces (H), were calculated 193 
for all studied compounds, taurocholate and lecithin from their SMILES structures using the 194 
Yamamoto molecular break (Y-MB) tool in HSPiP 25. The Y-MB tool uses a group contribution 195 
routine to calculate Hansen parameters based on molecular structure. Hansen parameters for a 196 
lipid aggregate phase were calculated based on the molar ratios of taurocholate and lecithin 197 
(4:1) in the BDM assuming that all lipids are present in the lipid phase and omitting the 198 
possibility that a fraction of the taurocholate is involved in smaller aggregates or as monomers 199 
in the aqueous phase. The Hansen distance (Hansen), as a measure on similarity between 200 
solvent and solute, was calculated based on the solubility parameters for drug-water 201 
(Hansenwater) and drug-mixed lipid aggregate (HansenMLA) according to Equation 2 
25. 202 
𝐻𝑎𝑛𝑠𝑒𝑛 = √
4 × (𝛿𝐷𝑆𝑜𝑙𝑢𝑡𝑒 − 𝛿𝐷𝑆𝑜𝑙𝑣𝑒𝑛𝑡)2
  +  (𝛿𝑃𝑆𝑜𝑙𝑢𝑡𝑒 − 𝛿𝑃𝑆𝑜𝑙𝑣𝑒𝑛𝑡)2
   + (𝛿𝐻𝑆𝑜𝑙𝑢𝑡𝑒 − 𝛿𝐻𝑆𝑜𝑙𝑣𝑒𝑛𝑡)2
  Equation 2. 203 
A low Hansen would indicate similarity between the drug and the media and therefore 204 
result in a higher solubility, while a high Hansen indicates that the solvent and solute are not 205 
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similar leading to a lower solubility, or solubilization in the case of drug solubilization in mixed 206 
lipid aggregates present in BDM. 207 
2.2.5 Statistical Analysis 208 
The logSRs for the drugs in each BDM were correlated to drug physicochemical 209 
properties (drug ionization, drug lipophilicity, molecular weight) and media characteristics 210 
(bile salt levels) by partial least squares (PLS) regression using the XLSTAT software 211 
(Microsoft, USA). Three models for the logSR of the neutral drugs (Model 1), weak bases 212 
(Model 2) and weak acids (Model 3) in the BDM were constructed. The evaluated variables 213 
were all numerical: i. bile salt concentration (BS), ii. % of drug ionized (Fion; calculated based 214 
on the Henderson – Hasselbalch equation at the pH of 6.5), iii. drug lipophilicity (log DpH 6.5), 215 
iv. molecular weight (MW) and v. melting temperature (Tm, Table 1). The calculated logSR 216 
(section 2.2.4) was set as response. The selected interaction terms included the level of bile 217 
salts combined with each drug physicochemical property (drug ionization, drug lipophilicity, 218 
molecular weight, melting temperature). The generated models were assessed in terms of 219 
goodness of prediction (Q2) and goodness of fit (R2). Q2 > 0.5 26 and R2 and Q2 values with a 220 
difference not greater than 0.2 - 0.3 27 were indications of acceptable models. The number of 221 
PLS components (lines on the X-space which best approximate and correlate with the Y-vector) 222 
was selected as described previously 24. Standardized coefficients were used to show the 223 
direction (positive or negative) and extent of each variable on the response. The significance 224 
of the variables was assessed by the variable influence on projection (VIP) value. VIP values 225 
> 0.8 were considered as moderately influential in the model while VIP values > 1 were 226 
considered the most influential in the model 27. A 95 % confidence interval was used.  227 
To further explore molecular properties related to drug-mixed lipid aggregate affinity 228 
and solubilization, more than 80 descriptors were calculated using HSPiP, DataWarrior 28, 229 
Chemaxon Excel 29 and SwissADME 30. Descriptors without information and duplicate 230 
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descriptors (i.e MW from 3 out of 4 software) were removed. The 64 remaining calculated 231 
descriptors were, together with clogppH6.5, assessed for correlation to logSR for all compounds 232 
in BDMH. 233 
3.Results and Discussion 234 
3.1 Solubility studies 235 
The apparent solubility values of the studied drugs in PhBpH 6.5 are presented in Table 236 
1 (for all compounds, apparent solubility values in PhBpH 6.5 have been experimentally 237 
determined for the purposes of this study, except from the values of danazol, astemizole and 238 
carvedilol, which have been previously determined experimentally by the authors 31). 239 
Neutral drugs: A range of apparent solubility values was observed (1.8-324 μM) in PhBpH 6.5 240 
explained by the varying lipophilicity of the studied neutral compounds; highly lipophilic drugs 241 
exhibited lower apparent solubility at 24 hr 32. Only progesterone slightly deviates from the 242 
above observation, despite its high lipophilicity which can be attributed to its lower molecular 243 
weight 32 or low melting temperature (Table 1). The effects of media with various bile salt 244 
levels on drug apparent solubility are shown in Figure 2. For this set of compounds, an 245 
enhancement in drug apparent solubility (0.18 < logSR < 1.77) was observed in the presence 246 
of lipidic components, due to their solubilization capacity 5. To be noted that for corticosterone 247 
in BDML and BDMM (logSR of approximately -0.10 in both media) and for danazol in BDML 248 
(logSR = -0.17), the data reveal that the apparent solubility values in the aforementioned cases 249 
were lower when compared to the PhBpH 6.5. This can be attributed to interday (corticosterone) 250 
or interlaboratory (danazol) variability. The fact that apparent solubility values in BDML for 251 
both compounds and in BDMM for corticosterone were not anticipated to greatly differ as 252 
compared in PhBpH 6.5 due to the low bile salt concentrations and the lipophilicity of 253 
corticosterone which lies in the lower limit (≈2) of the high lipophilicity criterion (Table 1), 254 
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respectively, is considered a contributing factor for the observed logSR. When comparing the 255 
results within the different BDMs, a general trend was observed with greater solubility 256 
enhancement for danazol, progesterone and felodipine than corticosterone and griseofulvin 257 
(Figure 2). As the studied neutral compounds are unionized and comprise of a narrow range 258 
of molecular weight (MW ≈ 350), it is reasonable to conclude that the above finding relates to 259 
the differences in drug lipophilicity; danazol, progesterone and felodipine (log DpH 6.5 > 3) 260 
benefit more from the presence and increased concentrations of mixed aggregates. Assuming 261 
that the theory of drug solubilization in mixed aggregates is governed by the two-state model 262 
(in which aggregates are considered a separate phase and drug partitioning resembles the one 263 
between a bulk organic solvent and water 33), the impact of drug lipophilicity in the 264 
solubilization process is not surprising.  265 
Weak bases: As per neutral compounds, the apparent solubility values of weak bases in PhBpH 266 
6.5 varied (1.1-2312.8 μM) as the studied compounds comprised of a wide range of 267 
physicochemical properties (Table 1). The differences in the apparent solubility values are 268 
mostly explained by the differences in drug lipophilicity, as highly lipophilic compounds 269 
exhibited, in general, lower apparent solubility 32. Only for dipyridamole and astemizole, 270 
apparent solubility values at 24 hr were considerably low which is likely explained by their 271 
pKa and low ionization in the studied medium. Presence of bile salts in BDML (0.07 < logSR 272 
< 0.58), BDMM (0.20 < logSR < 1.98) and BDMH (0.36 < logSR < 2.77) enhanced the apparent 273 
solubility of all studied weak bases. For dipyridamole (logSR = -0.01) and astemizole (logSR 274 
= -0.18), a reduction in the apparent solubility was observed in BDML attributed to similar 275 
factors (e.g. variability) as explained for neutral drugs. Understanding the effects of bile salt 276 
presence on the apparent solubility of weak bases requires a more profound look on the 277 
physicochemical drug properties. For the highly ionized drugs, the impact of bile salts on drug 278 
apparent solubility seems to differ for drugs with log DpH 6.5 < 0 (disopyramide), log DpH 6.5 ≈ 279 
13 
 
2 (carvedilol, haloperidol) and log DpH 6.5 > 4 (cinnarizine, tamoxifen). For disopyramide, 280 
although apparent solubility values were higher in the BDMs compared to PhBpH 6.5, 281 
pronounced differences in drug apparent solubility when increasing the bile salt levels were 282 
not observed (Figure 2). For carvedilol and haloperidol increasing the bile salts resulted in an 283 
improvement in drug apparent solubility [logSR up to approximately 0.56] but not to the same 284 
extent as for the cinnarizine and tamoxifen for which logSR were profoundly high, especially 285 
in BDMM and BDMH [0.81 < logSR <2.77). Mixed aggregates can bind ionized and unionized 286 
drugs but at different binding constants 34. Ionized weak bases should be able to bind to the 287 
negatively charged mixed aggregates 35 at some extent due to their positive charges. An 288 
interplay is observed between drug ionization and drug lipophilicity, in this study, as highly 289 
lipophilic and highly ionized weak bases will benefit more with increasing bile salt levels when 290 
compared to low lipophilic but highly ionized weak bases. The high driving force for partition 291 
in lipidic phases of highly lipophilic compounds seems to diminish the unfavourable effects of 292 
drug ionization for partition in mixed aggregates. For drugs that are poorly ionized in the 293 
studied media (dipyridamole, astemizole), the increase in drug apparent solubility in BDMM 294 
and BDMH is similar or even greater (Figure 2) when compared to highly ionized drugs of low 295 
or average lipophilicity. Although for astemizole, the observation is not surprising due to the 296 
high drug lipophilicity (logDpH6.5 = 4.4), it is of particular note for dipyridamole which is a 297 
compound of average lipophilicity (log DpH6.5 = 1.8) and should not exhibit higher logSR when 298 
compared to the other two weak bases of average lipophilicity (carvedilol, haloperidol). The 299 
dipyridamole example demonstrates, therefore, the importance of drug ionization on the 300 
affinity of drugs to mixed lipids; drugs of average lipophilicity will still partition to a great 301 
extent into mixed aggregates when they are not completely ionized.  302 
Weak acids: Similarly to the other two chemical drug classes, a wide range of apparent 303 
solubility values was found for weak acids (126-3438 μM) and as a general trend compounds 304 
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with log DpH 6.5 > 2 exhibited lower apparent solubility as compared to compounds with log 305 
DpH 6.5 < 2 (Table 1). Improvement in drug apparent solubility was observed in the BDMs for 306 
all studied compounds [0.04 < logSR < 0.60) except from the cases of indomethacin in BDMM 307 
(logSR== -0.04±0.02) and of warfarin in BDML [logSR = -0.54±0.04] and BDMM [logSR = -308 
0.20±0.01) (Figure 2). The pronounced reduction in warfarin apparent solubility, especially in 309 
SIFL, raises questions on whether this observation relates solely to experimental variability and 310 
requires further investigation; nonetheless warfarin was not excluded from this data set as it 311 
represents the most lipophilic weak acid and a clear dependency of drug apparent solubility at 312 
24 hr on bile salt concentration was observed. As per weak bases, two distinct cases were found 313 
in which experimental findings can be discussed: i. weak acids with log DpH 6.5 < 2 314 
(indomethacin, naproxen, indomethacin) and ii. weak acids with log DpH 6.5 > 2 (tolfenamic 315 
acid, warfarin). In the former case, the improvement in drug apparent solubility in presence of 316 
bile salts was minor [logSR up to approximately 0.11] and increase in bile salts levels did not 317 
greatly improve apparent drug solubility. Weak acids are negatively charged in the studied 318 
media and their negative charge is the predominant factor in drug partition to mixed aggregates 319 
when compared to their lipophilicity 36. In the latter case, drug apparent solubility was greatly 320 
improved [0.21 < logSR < 0.60] in BDMM and BDMH (except from the case of warfarin in 321 
BDMM). This observation once more illustrates a complex interplay between drug ionization 322 
and drug lipophilicity in the affinity of drug to mixed aggregates, as explained for the weak 323 
bases. 324 
The solubility studies revealed that drug concentrations can greatly be increased in media 325 
simulating the gastrointestinal fluids when solubilizing components are of concern. The extent 326 
of apparent solubility improvement depends on the physicochemical properties of active 327 
compounds; a dependency that needs to be properly delineated and accounted for. A number 328 
of physicochemical properties are considered critical for the affinity of drug to mixed lipid 329 
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aggregates (e.g. molecular size, charge, polarity), with lipophilicity being the most influential 330 
one 21. Predictive models to understand the solubilization capacity of bile salts based on drug 331 
lipophilicity have been developed 5. However it has been shown that drug lipophilicity solely 332 
is not always sufficient to explain the observed solubilization effects 37. The findings of this 333 
study demonstrate that the critical physicochemical properties dictating drug partitioning into 334 
mixed aggregates may differ according to drug chemical class. For neutral compounds 335 
lipophilicity explained majority of the effects of mixed lipid aggregates on drug apparent 336 
solubility, but for weak bases and weak acids, a strong interplay between drug lipophilicity and 337 
drug ionization was portrayed. Interestingly, it is noted that despite the beneficial role of bile 338 
salts in drug solubilization, attention is drawn as the profound differences in drug apparent 339 
solubility indicate that variations in the levels of these lipidic components in vivo can induce 340 
immense changes in the concentrations of drugs in the gastrointestinal lumen that could harm 341 
the patient (e.g. toxic drug levels in bloodstream) or impose regulatory challenges in product 342 
approvals (e.g. bioequivalence studies). 343 
3.2. Affinity of lipophilic compounds to mixed lipid aggregates in simulated 344 
intestinal fluids 345 
Hansen solubility parameters were calculated for all studied drugs, water, pure 346 
taurocholate, pure lecithin and finally mixed lipid aggregates. To assess the drugs affinity, or 347 
preference, between the aqueous phase and mixed lipid aggregate phase, Hansen were 348 
calculated based on the difference in the parameters between solutes and solvents (water and 349 
mixed lipid aggregates. Parameters and Hansen are presented in Table 3. To summarize the 350 
results, all studied drugs had higher Hansenwater than HansenMLA indicating that they are 351 
more similar to the mixed lipid aggregates than the aqueous phase. This is not surprising given 352 
their relatively high MW and lipophilic nature. Dipyridamole was the most water like drug 353 
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with the datasets lowest Hansenwater of 33.6. Corticosterone, that indeed has a similar 354 
molecular structure as taurocholate, was the compound with the lowest HansenMLA. 355 
Cinnarizine and progesterone were the compounds with the highest Hansenwater indicating 356 
that they are least water like compounds. Cinnarizine was also the drug with highest 357 
HansenMLA, or least similar to the mixed lipid aggregates. An interesting result was the large 358 
difference in Hansenwater for progesterone (41.4) and corticosterone (33.6) with similar 359 
molecular structures (Figure 1). The two additional hydroxyl groups in the latter affect both 360 
the p and h parameter strongly. 361 
In an attempt to better outline the affinity of lipophilic compounds in mixed lipid 362 
aggregates in the studied BDMs, apparent solubility data at 24 hr have been plotted and 363 
regressed against the levels of bile salts. The regression plots for neutral drugs, weak bases and 364 
weak acids are presented in Figures 3, 4 and 5, respectively. The regression plots do not take 365 
into account the solubility data in PhBpH 6.5; regression lines with the solubility data in PhBpH 366 
6.5 have been generated and reduction in the goodness of fit (reduction in the R
2 ranged between 367 
approximately 0.0001-0.3000 units) was observed for the majority of models. This was 368 
expected as large differences between the apparent solubility values in PhBpH 6.5 and BDML 369 
were not expected due to the low bile salt levels in the latter medium; data interpretation and 370 
conclusions drawn from these plots do not change. 371 
For neutral drugs, a linear dependency between the increase in the apparent drug solubility and 372 
bile salt concentrations was observed with high values of goodness of fit (R2 > 0.89) (Figure 373 
3). The ability of bile salts to form mixed aggregates with lecithin depends on the concentration 374 
of these lipidic components and it is known that at the levels introduced in BDML (medium 375 
simulating the bile salt/lecithin concentrations in the achlorhydric stomach) predominantly the 376 
wetting abilities of bile salts prevail 5. Mixed lipid aggregates (as explained in section 2.2.2.), 377 
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able to solubilize lipophilic compounds, are expected to be formed in the other two simulated 378 
media and explain the pronounced observed increase in drug solubility. The extent of 379 
solubilization in mixed aggregates strongly depends on the properties of both bile salts (e.g. 380 
concentration) and drug (e.g. size, charge and lipophilicity) 21. As the studied neutral 381 
compounds have an average molecular weight, are uncharged and exhibit average or high 382 
lipophilicity, their solubilization should mainly depend on the bile salt levels. As already 383 
reported in literature, the presence of more solubilizing components in the medium increases 384 
the apparent solubility of neutral compounds 34. The observed linear dependency indicates that, 385 
at least at the studied range of bile salt levels (0.08-7.5 mM), there are no confounding factors 386 
affecting the solubilization of neutral drugs in mixed aggregates; the bile salt levels, along with 387 
drug lipophilicity, mainly dictate drug solubilization.  388 
For weak bases, a linear dependency between drug apparent solubility and bile salt 389 
concentrations is observed for the majority of compounds (R2 > 0.85 for dipyridamole, 390 
astemizole, carvedilol, haloperidol, tamoxifen) (Figure 4). For these compounds, it is evident 391 
that their diffusion and partition into the mixed aggregates depends on the concentration of the 392 
lipidic components, as per the neutral compounds. Although, the aforementioned drugs are 393 
partially (dipyridamole, astemizole) or fully ionized (carvedilol, haloperidol, tamoxifen) in the 394 
studied media, it is noted that due to the negative net charge of aggregates, weak bases will be 395 
adequately solubilized in the aggregates, despite their ionization 34. In two cases, regression 396 
fits were poor (disopyramide, R2 = 0.25) or moderate (cinnarizine, R2 = 0.65). For 397 
disopyramide, the data can be attributed to the hydrophilic nature of the ionized species (log 398 
DpH 6.5 = -0.3) suggesting that variation in bile salts is not a critical parameter for highly ionized 399 
poorly lipophilic drugs. Based on the generated dataset, a good correlation between the increase 400 
in apparent solubility values of cinnarizine and the increase in bile concentrations was 401 
anticipated although not observed due to its high lipophilicity (logDpH6.5 = 4.3). Additional 402 
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investigations are required to explain the behavior of this drug, as none of its physicochemical 403 
properties (molecular weight, ionization, lipophilicity) can explain the lack of a good fit. 404 
Cinnarizine is the studied compound with the highest calculated HansenMLA. The large 405 
difference between cinnarizine’s and the mixed lipid aggregate solubility parameters indicate 406 
a poor solute-solvent match despite the drugs high lipophilicity which could relate to the 407 
comparatively low observed solubilization. Furthermore, the central and shielded location of 408 
cinnarizine’s basic nitrogens (Figure 1) may reduce the possibility of electrostatic interaction 409 
with the negatively charged lipid aggregates and may also be a reason for the lack of good fit 410 
between lipid contents and solubilization.    411 
For weak acids, poor correlations were observed for indoprofen (R2 = 0.46), naproxen (R2 = 412 
0.64) and indomethacin (R2 = 0.59) (Figure 5). The aforementioned compounds comprise of 413 
average lipophilicity (0.7 < logDpH6.5 < 1.3) and are completely ionized in the studied 414 
biorelevant media. This is not of surprise as these negatively charged molecules cannot easily 415 
diffuse through the negatively charged aggregates 34. On the contrary, a good correlation 416 
between drug and bile salt concentration was only observed for tolfenamic acid (R2 = 0.99) and 417 
warfarin (R2 = 0.99). Despite their ionization and negative charge, these two compounds are 418 
very lipophilic (log DpH 6.5 ≥ 2). It is evident therefore, that the impact of drug ionization on 419 
drug affinity to the mixed aggregates is diminished and the beneficial impact of drug 420 
lipophilicity on drug partitioning into the mixed aggregates prevails in this case. This 421 
investigation for weak bases and weak acids reveals that a more complex interplay between 422 
bile salt levels and drug physicochemical properties on drug solubilization exists.  423 
 424 
3.3. Multivariate Data Analysis 425 
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PLS was conducted to delineate the key biopharmaceutical factors affecting the affinity 426 
and solubilization of drugs in mixed aggregates. These models are not used as predictive, due 427 
to the absence of validation methods, but mainly to understand how different drug classes are 428 
solubilized in the mixed lipid aggregates of the studied media. The standardized coefficients of 429 
the variables in each model (neutral compounds, weak bases, weak acids) are presented in 430 
Figure 6. For neutral drugs, the model showed high goodness of prediction (Q2 = 0.90) and fit 431 
(R2 = 0.95) which is an indication that the studied biopharmaceutical variables adequately 432 
explain the affinity of lipophilic compounds to mixed aggregates. Log DpH=6.5 (positive effect, 433 
VIP = 2.06), MW (positive effect, VIP = 1.46), BS (positive effect, VIP = 1.16) and Tm 434 
(negative effect, VIP = 1.01) were the significant variables in this model. The significance of 435 
log DpH=6.5 confirms that highly lipophilic drugs have higher affinity and are better solubilized 436 
by bile salts, due to the lipophilic nature of the endogenous components of the gastrointestinal 437 
tract. Surprisingly, the model indicates that neutral drugs of higher MW will, as well, be greatly 438 
solubilized in the lipid aggregates. Although this finding tackles fundamentals aspects, as larger 439 
compounds are not expected to be adequately solubilized 38, it should be noted that the studied 440 
neutral drugs comprised of average molecular weight (MW ≈ 300-400) and that this conclusion 441 
should not be extrapolated to larger molecules (MW > 400 - 500). Increasing the levels of 442 
mixed lipid aggregates in the medium will significantly increase the solubility of neutral 443 
compounds, as indicated by the significance of the variable BS. Finally, the negative effect of 444 
the Tm variable suggests that the solubility of compounds with high crystal lattice energies will 445 
be less influenced (increase) by the presence of bile salts. For weak bases, the model showed 446 
adequate goodness of prediction (Q2 = 0.51) and fit (R2 = 0.65) revealing that the studied 447 
biopharmaceutical variables included can partially explain the observed effects of bile salts on 448 
drug apparent solubility. Log DpH=6.5 (positive effect, VIP = 1.46), BS (positive effect, VIP = 449 
1.34), Tm (negative effect, VIP = 1.31), MW (negative effect, VIP = 1.13) and F(ion) (positive 450 
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effect, VIP = 1.03) were the most influential main variables in the model. The statistical model 451 
reveals that the enhancement in drug solubility will be more pronounced for highly lipophilic 452 
weak bases and with increasing levels of bile salts, as indicated by the significance of the log 453 
DpH=6.5 and BS variables, respectively. In addition, it is suggested that molecules with strong 454 
intermolecular forces or of larger size will benefit in a lower extent by the solubilizing capacity 455 
of the bile salts. In the case of weak bases, highly ionized molecules can still be solubilized by 456 
mixed lipid aggregates (due to the negative net charge of the latter, as explained in section 3.1) 457 
and this is considered a significant factor by the model. Understanding the affinity of weak 458 
bases to mixed aggregates is more complex, when compared to neutral drugs, as indicated by 459 
the significance of the interaction terms BS*logDpH 6.5 (positive effect, VIP = 0.92). This 460 
interaction term reveals an interplay, as the enhancement in drug solubility by increasing the 461 
bile salt levels will be more pronounced for high, as compared to low, lipophilic compounds. 462 
Finally, for weak acids the model showed adequate goodness of prediction (Q2 = 0.82) and fit 463 
(R2 = 0.89). BS (positive effect, VIP = 1.57) and logDpH 6.5 (negative effect, VIP = 0.82) were 464 
the most critical main variables in the model, while BS*F(ion) (negative effect, VIP = 1.39), 465 
BS*log DpH 6.5 (positive effect, VIP = 1.19) and BS*Tm (positive effect, VIP = 0.86) were the 466 
most influential interaction terms. The conclusions drawn by the significance of the BS match 467 
the ones observed for weak bases. The negative effect of the logDpH 6.5 variable needs to be 468 
interpreted with caution, as it may reflect the case of warfarin for which significant low log(SR) 469 
were observed. The model was able to capture the interplay of bile salt levels and drug 470 
lipophilicity (as revealed by the BS*log DpH 6.5 interaction term) as increasing the bile salt 471 
levels will enhance the solubilization of highly lipophilic compounds to mixed aggregates. For 472 
weak acids, increasing their ionization will diminish the positive effects (increase) of bile salts 473 
on drug solubility, as due to their negative charge, weak acids are less likely to be solubilized 474 
by the mixed lipid aggregates. Interestingly, it was revealed that high levels of bile salts will 475 
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significantly enhance the solubility of compounds with high Tm, as indicated by the 476 
significance of the BS*Tm interaction term. Among the calculated descriptors associated with 477 
high SR in BDMH, most were linked to lipophilicity (clogDpH6.5, clogP, ASAhydrophobic -478 
accessible molecular surface area of all hydrophobic atoms 29) and size (Min proj Area - 479 
minimum of projection area based on van der Waals radius, and Mvol - molecular volume), 480 
but polarizability, ovality and positive charge (ASAplus - water accessible molecular surface 481 
area of all atoms with positive partial charge) were also correlated with a high degree of 482 
solubilization. Polar surface area, acidity (number of acidic oxygens) and hydrogen bonding 483 
capability (δH 25) were on the other hand correlated to lower SR or solubilization.   484 
4. Conclusions 485 
The presence of endogenous lipidic components in vivo, such as bile salts and phospholipids, 486 
is beneficial for oral drug absorption, as these components can form mixed micelles able to 487 
solubilize lipophilic compounds and subsequently improve oral drug absorption. In the 488 
gastrointestinal lumen, variability in the molecular/structural properties or levels of mixed 489 
micelles is challenging and may affect not only drug concentrations in the gastrointestinal tract 490 
but, also, complicate the outcome of in vivo bioavailability/bioequivalence studies. In this 491 
study, the impact of increasing levels of bile salts on the 24-hr drug solubility was assessed. 492 
Solubility studies revealed pronounced improvement in drug solubility when increasing bile 493 
salts concentrations, which greatly depended on drug chemical class and drug physicochemical 494 
properties. Hansen solubility parameters can be used to estimate the solubility of a solute in a 495 
solvent based on their similarity in terms polarity, dispersion forces and their ability to form 496 
hydrogen bonds. The parameters do not take solid state interactions, apparent solubility 497 
increase due to ionization or aggregation into account but it may be able to provide additional 498 
information on why or why not a drug is strongly solubilized in mixed lipid aggregates present 499 
in BDMs. 500 
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These solubility data highlight that, in vivo, profound changes in drug concentrations would 501 
be anticipated due to bile salt variability which need to be further investigated and adequately 502 
accounted for when designing in vitro or in vivo studies. Use of statistical tools (regression 503 
plots, multivariate data analysis) revealed the complex nature of drug affinity to mixed 504 
aggregates and provided a first insight on the drug cases in which bile salt (level) and/or drug 505 
properties (ionization, lipophilicity, molecular weight) are critical and need additional 506 
considerations. As enabling strategies are often selected to formulate poorly soluble 507 
compounds, future incorporation of formulation (surfactants, lipids) and digestion factors to 508 
investigate their interplay on the affinity of lipophilic compounds to mixed lipid aggregates 509 
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Figure captions 639 
Figure 1: Structure of the studied compounds. 640 
Figure 2: Logarithm of solubility ratios of the different bile salt levels on the apparent solubility of neutral drugs (red colour), weak bases (green 641 
colour) and weak acids (blue colour). Colour shades represent the biorelevant dissolution media (BDM); gradual changes from light to dark colours 642 
indicate media of increasing bile salt concentrations (Mean±SD, n=3). 643 
Figure 3: Drug apparent solubility values of neutral compounds as a function of bile salt concentration. Lines represent the best fit of the regression 644 
model. Dashed lines represent the 95% confidence intervals. Boxes indicate the slope of the regression line (Mean±SE, n=3) and the goodness of 645 
fit. 646 
Figure 4: Drug apparent solubility values of weak bases as a function of bile salt concentration. Lines represent the best fit of the regression model. 647 
Dashed lines represent the 95% confidence intervals. Boxes indicate the slope of the regression line (Mean±SE, n=3) and the goodness of fit. 648 
Figure 5: Drug apparent solubility values of weak acids as a function of bile salt concentration. Lines represent the best fit of the regression model. 649 
Dashed lines represent the 95% confidence intervals. Boxes indicate the slope of the regression line (Mean±SE, n=3) and the goodness of fit. 650 
Figure 6: a. Standardized coefficients of the studied variables (and interaction terms) for neutral drugs (red colour), weak bases (green colour) and 651 
weak acids (blue colour). * denotes standardized coefficients of 0.8 < VIP < 1 while * denotes standardized coefficients of VIP > 1. (Mean, ± SE). 652 
b. Variable importance in the projection (VIP) of the studied variables (and interaction terms) for neutral drugs (red colour), weak bases (green 653 
29 
 
colour) and weak acids (blue colour). Dashed lines represent the criteria for selecting moderately influential (0.8 < VIP < 1) and influential (VIP 654 
> 1) variables. (Mean, ± SE). 655 
 656 





Table 1: Physicochemical properties and solubility values (μM) in PhBpH 6.5 (Mean±SD, n=3) of the selected compounds for solubility experiments. 660 
Chemical 
Class 







Corticosterone n.a. 0 2.2  346.5 181 324.4±28.6 
Griseofulvin n.a. 0 2.5  352.8 220 30.6±3.0 
Danazol n.a. 0 3.6  337.5 225 1.8±0.0 31 
Progesterone n.a. 0 3.8  314.5 121 28.4±0.3 








Disopyramide 9.89  99.9% -0.3  339.5 95 2312.8±159.6 
Dipyridamole 6.20  47.6% 1.7  504.7 163 12.7±0.3 
Haloperidol 8.55  99.1% 2.0  375.9 149 119.6±6.2 
Carvedilol 7.80  98.0% 2.4  406.5 114 113.2±2.5 31 
Cinnarizine 7.45  90.0% 4.3  368.6 120 4.1±0.1 
Astemizole 5.34  5.6% 4.4  458.6 173 41.9±0.4 31 







s Indoprofen 4.02  99.7% 0.7  281.3 214 1982.0±287.6
 
Naproxen 4.23  99.5% 1.3  230.3 153 3438.8±285.6 
Indomethacin 3.91  99.7% 1.5  357.8 155 987.3±61.6 
Warfarin 4.73  98.3% 2.0 308.4 161 329.8±16.8 
Tolfenamic acid 4.08  99.6% 2.9  261.7 207 126.0±4.4 
aExperimental values (Ref.39), bCalculated values (Ref. 39)661 
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Table 2: Composition of the phosphate buffer (PhBpH6.5) and biorelevant dissolution media (BDM). The solubility medium variants (sodium 662 
taurocholate and lecithin) are shown in the box. 663 
Component (mM) PhBpH 6.5 BDML BDMM BDMH 
Phosphates 29 29 29 29 
Sodium 148 148 148 148 
Chloride 106 106 106 106 
pH 6.5 6.5 6.5 6.5 
Sodium taurocholate - 0.08 1.50 7.50 




Table 3: Calculated Hansen Solubility Parameters for solvents (media) and solutes 
(compounds) and Hansen values for solvent-solute pairs. The parameters represent 
intermolecular dispersion forces (D), polarity forces (P) and hydrogen bond forces (H) 
respectively and Hansen similarity between solute and solvent pairs with a low value denoting 










Astemizole 20.1 5.9 5.2 39.5 9.5 
Carvedilol 20.2 6.5 7.4 37.3 7.8 
Cinnarizine 19 1.5 4.2 41.4 12.7 
Corticosterone 18.8 8.4 8.4 35.4 4.8 
Danazol 18.2 5.7 5.5 38.6 8.6 
Dipyridamol 20.5 15.7 10.2 33.6 6.4 
Disopyramide 17.9 6.4 4.3 39.4 9 
Felodipine 18.5 3.9 6.5 38.2 9.3 
Griseofulvin 20 9.8 6.1 37.8 7.1 
Haloperidol 19.5 7.2 6.9 37.3 7.1 
Indomethacin 20.7 6.5 6.9 38.1 8.7 
Indoprofen 20.4 5.5 8.6 36.6 8.2 
Naproxen 19.7 4 10.2 35.3 8.3 
Progesterone 18.6 5.3 2.7 41.4 11 
Tamoxifen 18.4 2.9 3.6 41.3 11.9 
Tolfenamic acid 20.4 6.1 9.4 35.7 7.5 
Warfarin 22 5 8 38.2 10.8 
Water 15.5 16 42.3 0 31.3 
TCA 18.6 12.9 12.4 30.7 1.8 
Lecithin 16.1 6.4 9.1 34.6 7.1 




















































Corticosterone 74.60 2 4 2 
Griseofulvin 71.06 3 6 0 
Danazol 46.26 0 3 1 
Progesterone 34.14 1 2 0 








Disopyramide 59.22 8 4 1 
Dipyridamole 145.44 12 12 4 
Haloperidol 40.54 6 3 1 
Carvedilol 75.74 10 6 3 
Cinnarizine 6.48 6 2 0 
Astemizole 42.32 8 5 1 







s Indoprofen 57.61 3 4 1 
Naproxen 46.53 3 3 1 
Indomethacin 68.53 5 5 1 
Warfarin 63.60 4 4 1 




Supplementary Table 2: HPLC methods used for drug quantification 1 
Substance Temp.(º
C) 





Astemizole1 40 ACN + formic acid 0.1 %   
20:80 
283 1.3-43.6 










40 MeOH + formic acid 0.1% 
60:40 
243 5.4-86.5 
Danazol5 25 MeOH: H2O 
85:15 
285 0.9-29.6 







40 ACN: H2O + formic acid 0.1% 
20:80 
261 11.0-176.7 
Felodipine 7 40 MeOH: H2O 
75: 25 
238 1.6-52.0 
Griseofulvin 8 25 MeOH: H2O 
65: 35 
292 0.8-14.1 
Haloperidol 9 40 ACN: H2O + formic acid 0.1% 
30:70 
230 4.9-79.8 
Indomethacin 8 25 MeOH: H2O+ formic acid 0.1% 70:30 270 10.4-167.7 
Indoprofen 10 40 ACN: H2O + formic acid 0.1% 
40:60  
280 26.6-426.6 
Naproxen 11 40 ACN + 0.1 % formic acid  
60:40 
239 2.7-86.9 
Progesterone 12 25 MeOH + H2O (70:30) 243 1.0-15.9 





40 MeOH: H2O +formic acid 0.1% 80:20 286 4.7-76.4 





The column used for all tested drugs was, Waters Xbridge Shield RP18, 130Å, 
150 X 4.6, 3.5 µm. The injection volume used was 100 µL for all drugs except 
for Indoprofen, 50 µL. Used flow rate was 0.8 mL/min for Griseofulvin and 1 
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